메뉴 건너뛰기




Volumn 11, Issue 3, 2015, Pages 363-375

Decitabine: A promising epi-immunotherapeutic agent in solid tumors

Author keywords

cancer testis antigen; co stimulatory molecules; decitabine; HLA class I; immune response; immunotherapy; methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CETUXIMAB; DNA VACCINE; HLA ANTIGEN CLASS 1; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; PANITUMUMAB; VORINOSTAT; AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE;

EID: 84923330650     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1002397     Document Type: Review
Times cited : (30)

References (149)
  • 1
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: From immunosurveillance to tumor escape
    • Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
    • (2002) Nat immunol , vol.3 , Issue.11 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3
  • 2
    • 34248193253 scopus 로고    scopus 로고
    • Immune surveillance of tumors
    • Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117(5): 1137-46
    • (2007) J Clin Invest , vol.117 , Issue.5 , pp. 1137-1146
    • Swann, J.B.1    Smyth, M.J.2
  • 5
    • 33846011361 scopus 로고    scopus 로고
    • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    • Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109(1):52-7
    • (2007) Blood , vol.109 , Issue.1 , pp. 52-57
    • Kantarjian, H.1    Oki, Y.2    Garcia-Manero, G.3
  • 6
    • 10744233452 scopus 로고    scopus 로고
    • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2?-deoxycytidine (decitabine) in hematopoietic malignancies
    • Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2?-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103(5):1635-40
    • (2004) Blood , vol.103 , Issue.5 , pp. 1635-1640
    • Issa, J.P.1    Garcia-Manero, G.2    Giles, F.J.3
  • 7
    • 0035988868 scopus 로고    scopus 로고
    • Review of the clinical experience with 5-Azacytidine and 5-Aza-2?-deoxycytidine in solid tumors
    • Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2?-deoxycytidine in solid tumors. Curr Opin Investig Drugs 2002;3(4):627-33
    • (2002) Curr Opin Investig Drugs , vol.3 , Issue.4 , pp. 627-633
    • Aparicio, A.1    Weber, J.S.2
  • 8
    • 77954122580 scopus 로고    scopus 로고
    • Will DNA methylation inhibitors work in solid tumors?. A review of the clinical experience with azacitidine and decitabine in solid tumors
    • Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors?. A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2010;2(1):71-86
    • (2010) Epigenomics , vol.2 , Issue.1 , pp. 71-86
    • Cowan, L.A.1    Talwar, S.2    Yang, A.S.3
  • 9
    • 84877574817 scopus 로고    scopus 로고
    • The future of epigenetic therapy in solid tumours-lessons from the past
    • Azad N, Zahnow CA, Rudin CM, et al. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 2013;10(5):256-66
    • (2013) Nat Rev Clin Oncol , vol.10 , Issue.5 , pp. 256-266
    • Azad, N.1    Zahnow, C.A.2    Rudin, C.M.3
  • 11
    • 0018860957 scopus 로고
    • Cellular differentiation, cytidine analogs and dna methylation
    • Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20(1):85-93
    • (1980) Cell , vol.20 , Issue.1 , pp. 85-93
    • Jones, P.A.1    Taylor, S.M.2
  • 12
    • 0037068379 scopus 로고    scopus 로고
    • 5-Azacytidine and 5-Aza-2?-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy
    • Christman JK. 5-Azacytidine and 5-Aza-2?-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21(35):5483-95
    • (2002) Oncogene , vol.21 , Issue.35 , pp. 5483-5495
    • Christman, J.K.1
  • 13
    • 29144517352 scopus 로고    scopus 로고
    • Decitabine: A historical review of the development of an epigenetic drug
    • de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005; 84(Suppl 1):3-8
    • (2005) Ann Hematol , vol.84 , pp. 3-8
    • De Vos, D.1    Van Overveld, W.2
  • 14
    • 0242539831 scopus 로고    scopus 로고
    • Epigenetic targets for immune intervention in human malignancies
    • Maio M, Coral S, Fratta E, et al. Epigenetic targets for immune intervention in human malignancies. Oncogene 2003;22(42): 6484-8
    • (2003) Oncogene , vol.22 , Issue.42 , pp. 6484-6488
    • Maio, M.1    Coral, S.2    Fratta, E.3
  • 15
    • 25844530904 scopus 로고    scopus 로고
    • Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy
    • Sigalotti L, Coral S, Fratta E, et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol 2005;32(5):473-8
    • (2005) Semin Oncol , vol.32 , Issue.5 , pp. 473-478
    • Sigalotti, L.1    Coral, S.2    Fratta, E.3
  • 16
    • 84878186386 scopus 로고    scopus 로고
    • Concise drug review: Azacitidine and decitabine
    • Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist 2013;18(5):619-24
    • (2013) Oncologist , vol.18 , Issue.5 , pp. 619-624
    • Derissen, E.J.1    Beijnen, J.H.2    Schellens, J.H.3
  • 17
    • 77952203695 scopus 로고    scopus 로고
    • S110 a 5-Aza-2?-deoxycytidine-containing dinucleotide is an effective dna methylation inhibitor in vivo and can reduce tumor growth
    • Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2?-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010;9(5):1443-50
    • (2010) Mol Cancer Ther , vol.9 , Issue.5 , pp. 1443-1450
    • Chuang, J.C.1    Warner, S.L.2    Vollmer, D.3
  • 18
    • 33645462696 scopus 로고    scopus 로고
    • Synthesis and in vitro evaluation of biotinylated rg108: A high affinity compound for studying binding interactions with human dna methyltransferases
    • Schirrmacher E, Beck C, Brueckner B, et al. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem 2006;17(2):261-6
    • (2006) Bioconjug Chem , vol.17 , Issue.2 , pp. 261-266
    • Schirrmacher, E.1    Beck, C.2    Brueckner, B.3
  • 19
    • 34648820287 scopus 로고    scopus 로고
    • Low dose zebularine treatment enhances immunogenicity of tumor cells
    • Liu H, Xue ZT, Sjogren HO, et al. Low dose Zebularine treatment enhances immunogenicity of tumor cells. Cancer Lett 2007;257(1):107-15
    • (2007) Cancer Lett , vol.257 , Issue.1 , pp. 107-115
    • Liu, H.1    Xue, Z.T.2    Sjogren, H.O.3
  • 20
    • 0035755974 scopus 로고    scopus 로고
    • Histone deacetylases and cancer: Causes and therapies
    • Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1(3): 194-202
    • (2001) Nat Rev Cancer , vol.1 , Issue.3 , pp. 194-202
    • Marks, P.1    Rifkind, R.A.2    Richon, V.M.3
  • 21
    • 67649371461 scopus 로고    scopus 로고
    • Dznep is a global histone methylation inhibitor that reactivates developmental genes not silenced by dna methylation
    • Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8(6):1579-88
    • (2009) Mol Cancer Ther , vol.8 , Issue.6 , pp. 1579-1588
    • Miranda, T.B.1    Cortez, C.C.2    Yoo, C.B.3
  • 22
    • 84899459437 scopus 로고    scopus 로고
    • Nonclinical pharmacokinetics and metabolism of epz-5676 a novel dot1l histone methyltransferase inhibitor
    • Basavapathruni A, Olhava EJ, Daigle SR, et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos 2014;35(4):237-52
    • (2014) Biopharm Drug Dispos , vol.35 , Issue.4 , pp. 237-252
    • Basavapathruni, A.1    Olhava, E.J.2    Daigle, S.R.3
  • 23
    • 77954121574 scopus 로고    scopus 로고
    • A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent platinum-resistant epithelial ovarian cancer
    • Fang F, Balch C, Schilder J, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010;116(17):4043-53
    • (2010) Cancer , vol.116 , Issue.17 , pp. 4043-4053
    • Fang, F.1    Balch, C.2    Schilder, J.3
  • 24
    • 66649105473 scopus 로고    scopus 로고
    • Decitabine effect on tumor global dna methylation and other parameters in a phase i trial in refractory solid tumors and lymphomas
    • Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009;15(11): 3881-8
    • (2009) Clin Cancer Res , vol.15 , Issue.11 , pp. 3881-3888
    • Stewart, D.J.1    Issa, J.P.2    Kurzrock, R.3
  • 25
    • 0034106513 scopus 로고    scopus 로고
    • A phase i trial of cisplatin plus decitabine, a new dnahypomethylating agent, in patients with advanced solid tumors and a follow-up early phase ii evaluation in patients with inoperable non-small cell lung cancer
    • Schwartsmann G, Schunemann H, Gorini CN, et al. A phase I trial of cisplatin plus decitabine, a new DNAhypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000;18(1):83-91
    • (2000) Invest New Drugs , vol.18 , Issue.1 , pp. 83-91
    • Schwartsmann, G.1    Schunemann, H.2    Gorini, C.N.3
  • 26
    • 84872316231 scopus 로고    scopus 로고
    • Phase i study of 5-Aza-2?-deoxycytidine in combination with valproic acid in non-small-cell lung cancer
    • Chu BF, Karpenko MJ, Liu Z, et al. Phase I study of 5-Aza-2?-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2013;71(1):115-21
    • (2013) Cancer Chemother Pharmacol , vol.71 , Issue.1 , pp. 115-121
    • Chu, B.F.1    Karpenko, M.J.2    Liu, Z.3
  • 27
    • 0031945210 scopus 로고    scopus 로고
    • A phase ii study of 5-Aza-2?deoxycytidine (decitabine) in hormone independent metastatic d2) prostate cancer
    • Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-Aza-2?deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998;84(1):87-9
    • (1998) Tumori , vol.84 , Issue.1 , pp. 87-89
    • Thibault, A.1    Figg, W.D.2    Bergan, R.C.3
  • 28
    • 84884818865 scopus 로고    scopus 로고
    • A phase i/ii study of decitabine in combination with panitumumab in patients with wild-Type (wt) kras metastatic colorectal cancer
    • Garrido-Laguna I, McGregor KA, Wade M, et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-Type (wt) KRAS metastatic colorectal cancer. Invest New Drugs 2013; 31(5):1257-64
    • (2013) Invest New Drugs , vol.31 , Issue.5 , pp. 1257-1264
    • Garrido-Laguna, I.1    McGregor, K.A.2    Wade, M.3
  • 29
    • 0030974771 scopus 로고    scopus 로고
    • Pilot phase i-ii study on 5-Aza-2?-deoxycytidine (decitabine) in patients with metastatic lung cancer
    • Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I-II study on 5-Aza-2?-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8(4):358-68
    • (1997) Anticancer Drugs , vol.8 , Issue.4 , pp. 358-368
    • Momparler, R.L.1    Bouffard, D.Y.2    Momparler, L.F.3
  • 30
    • 0035196111 scopus 로고    scopus 로고
    • Potential of 5-Aza-2?-deoxycytidine (decitabine) a potent inhibitor of dna methylation for therapy of advanced non-small cell lung cancer
    • Momparler RL, Ayoub J. Potential of 5-Aza-2?-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung cancer 2001;34(Suppl 4):S111-15
    • (2001) Lung Cancer , vol.34 , pp. S111-S115
    • Momparler, R.L.1    Ayoub, J.2
  • 31
    • 79952710830 scopus 로고    scopus 로고
    • Phase i study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin?s lymphomas
    • Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin?s lymphomas. Clin Cancer Res 2011;17(6):1582-90
    • (2011) Clin Cancer Res , vol.17 , Issue.6 , pp. 1582-1590
    • Stathis, A.1    Hotte, S.J.2    Chen, E.X.3
  • 32
    • 34548414620 scopus 로고    scopus 로고
    • Phase i and pharmacodynamic trial of the dna methyltransferase inhibitor decitabine and carboplatin in solid tumors
    • Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25(29):4603-9
    • (2007) J Clin Oncol , vol.25 , Issue.29 , pp. 4603-4609
    • Appleton, K.1    MacKay, H.J.2    Judson, I.3
  • 33
    • 77957039745 scopus 로고    scopus 로고
    • Phase i study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children?s oncology group study
    • George RE, Lahti JM, Adamson PC, et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children?s Oncology Group study. Pediatr Blood Cancer 2010;55(4): 629-38
    • (2010) Pediatr Blood Cancer , vol.55 , Issue.4 , pp. 629-638
    • George, R.E.1    Lahti, J.M.2    Adamson, P.C.3
  • 34
    • 84902201862 scopus 로고    scopus 로고
    • Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: A phase i/ii report
    • Fan H, Lu X, Wang X, et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res 2014;2014:371087
    • (2014) J Immunol Res , vol.2014 , pp. 371087
    • Fan, H.1    Lu, X.2    Wang, X.3
  • 35
    • 84910021131 scopus 로고    scopus 로고
    • Decitabine a new star in epigenetic therapy: The clinical application and biological mechanism in solid tumors
    • Nie J, Liu L, Li X, et al. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett 2014;354(1): 12-20
    • (2014) Cancer Lett , vol.354 , Issue.1 , pp. 12-20
    • Nie, J.1    Liu, L.2    Li, X.3
  • 36
    • 52949144622 scopus 로고    scopus 로고
    • Dna methylation: Its role in cancer development and therapy
    • Kurkjian C, Kummar S, Murgo AJ. DNA methylation: its role in cancer development and therapy. Curr Probl Cancer 2008;32(5):187-235
    • (2008) Curr Probl Cancer , vol.32 , Issue.5 , pp. 187-235
    • Kurkjian, C.1    Kummar, S.2    Murgo, A.J.3
  • 37
    • 40949087119 scopus 로고    scopus 로고
    • Dna methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
    • Barton CA, Hacker NF, Clark SJ, et al. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109(1):129-39
    • (2008) Gynecol Oncol , vol.109 , Issue.1 , pp. 129-139
    • Barton, C.A.1    Hacker, N.F.2    Clark, S.J.3
  • 38
    • 31544467532 scopus 로고    scopus 로고
    • Nutritional epigenetics: Impact of folate deficiency on dna methylation and colon cancer susceptibility
    • Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 2005; 135(11):2703-9
    • (2005) J Nutr , vol.135 , Issue.11 , pp. 2703-2709
    • Kim, Y.I.1
  • 39
    • 84923367056 scopus 로고    scopus 로고
    • Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes fhit wwox fus1 and pten in clinical tumor samples
    • Stewart DJ, Nunez MI, Jelinek J, et al. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics 2014;6(1): 13
    • (2014) Clin Epigenetics , vol.6 , Issue.1 , pp. 13
    • Stewart, D.J.1    Nunez, M.I.2    Jelinek, J.3
  • 40
    • 33750326078 scopus 로고    scopus 로고
    • Phase i study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
    • Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12(19):5777-85
    • (2006) Clin Cancer Res , vol.12 , Issue.19 , pp. 5777-5785
    • Schrump, D.S.1    Fischette, M.R.2    Nguyen, D.M.3
  • 41
    • 4744355872 scopus 로고    scopus 로고
    • Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression
    • Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53(10): 844-54
    • (2004) Cancer Immunol Immunother , vol.53 , Issue.10 , pp. 844-854
    • Ahmad, M.1    Rees, R.C.2    Ali, S.A.3
  • 42
    • 0036157853 scopus 로고    scopus 로고
    • Hla class i antigen abnormalities and immune escape by malignant cells
    • Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12(1):3-13
    • (2002) Semin Cancer Biol , vol.12 , Issue.1 , pp. 3-13
    • Seliger, B.1    Cabrera, T.2    Garrido, F.3
  • 43
    • 84877355904 scopus 로고    scopus 로고
    • Low dose decitabine treatment induces cd80 expression in cancer cells and stimulates tumor specific cytotoxic t lymphocyte responses
    • Wang LX, Mei ZY, Zhou JH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One 2013;8(5): e62924
    • (2013) PLoS One , vol.8 , Issue.5 , pp. e62924
    • Wang, L.X.1    Mei, Z.Y.2    Zhou, J.H.3
  • 44
    • 84872648991 scopus 로고    scopus 로고
    • Cancer testis antigens: A new paradigm for cancer therapy
    • Suri A, Saini S, Sinha A, et al. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology 2012;1(7): 1194-6
    • (2012) Oncoimmunology , vol.1 , Issue.7 , pp. 1194-1196
    • Suri, A.1    Saini, S.2    Sinha, A.3
  • 45
    • 0036911269 scopus 로고    scopus 로고
    • Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells
    • Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002;17(6):737-47
    • (2002) Immunity , vol.17 , Issue.6 , pp. 737-747
    • Spiotto, M.T.1    Yu, P.2    Rowley, D.A.3
  • 46
    • 23144464171 scopus 로고    scopus 로고
    • Cancer/testis antigens, gametogenesis and cancer
    • Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5(8): 615-25
    • (2005) Nat Rev Cancer , vol.5 , Issue.8 , pp. 615-625
    • Simpson, A.J.1    Caballero, O.L.2    Jungbluth, A.3
  • 47
    • 0037364292 scopus 로고    scopus 로고
    • Cancer/testis-Associated genes: Identification, expression profile, and putative function
    • Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-Associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194(3):272-88
    • (2003) J Cell Physiol , vol.194 , Issue.3 , pp. 272-288
    • Zendman, A.J.1    Ruiter, D.J.2    Van Muijen, G.N.3
  • 48
    • 24744440159 scopus 로고    scopus 로고
    • Conditional expression of the ctcf-paralogous transcriptional factor boris in normal cells results in demethylation and derepression of mage-A1 and reactivation of other cancer-Testis genes
    • Vatolin S, Abdullaev Z, Pack SD, et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-Testis genes. Cancer Res 2005;65(17): 7751-62
    • (2005) Cancer Res , vol.65 , Issue.17 , pp. 7751-7762
    • Vatolin, S.1    Abdullaev, Z.2    Pack, S.D.3
  • 49
    • 24744448032 scopus 로고    scopus 로고
    • Reciprocal binding of ctcf and boris to the ny-eso-1 promoter coincides with derepression of this cancer-Testis gene in lung cancer cells
    • Hong JA, Kang Y, Abdullaev Z, et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-Testis gene in lung cancer cells. Cancer Res 2005;65(17): 7763-74
    • (2005) Cancer Res , vol.65 , Issue.17 , pp. 7763-7774
    • Hong, J.A.1    Kang, Y.2    Abdullaev, Z.3
  • 50
    • 0036023437 scopus 로고    scopus 로고
    • 5-Aza-2?-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: Immunotherapeutic implications
    • Coral S, Sigalotti L, Altomonte M, et al. 5-Aza-2?-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8(8):2690-5
    • (2002) Clin Cancer Res , vol.8 , Issue.8 , pp. 2690-2695
    • Coral, S.1    Sigalotti, L.2    Altomonte, M.3
  • 51
    • 84894106057 scopus 로고    scopus 로고
    • Epigenetic potentiation of ny-eso-1 vaccine therapy in human ovarian cancer
    • Odunsi K, Matsuzaki J, James SR, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2(1):37-49
    • (2014) Cancer Immunol Res , vol.2 , Issue.1 , pp. 37-49
    • Odunsi, K.1    Matsuzaki, J.2    James, S.R.3
  • 52
    • 84863138984 scopus 로고    scopus 로고
    • Epigenetic modulation to enable antigen-specific t-cell therapy of colorectal cancer
    • Chou J, Voong LN, Mortales CL, et al. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 2012;35(2):131-41
    • (2012) J Immunother , vol.35 , Issue.2 , pp. 131-141
    • Chou, J.1    Voong, L.N.2    Mortales, C.L.3
  • 53
    • 80355131506 scopus 로고    scopus 로고
    • Decitabine immunosensitizes human gliomas to ny-eso-1 specific t lymphocyte targeting through the fas/fas ligand pathway
    • Konkankit VV, Kim W, Koya RC, et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med 2011;9:192
    • (2011) J Transl Med , vol.9 , pp. 192
    • Konkankit, V.V.1    Kim, W.2    Koya, R.C.3
  • 54
    • 77953272279 scopus 로고    scopus 로고
    • Effect of 5-Aza-2?-deoxycytidine on immune-Associated proteins in exosomes from hepatoma
    • Xiao WH, Sanren GW, Zhu JH, et al. Effect of 5-Aza-2?-deoxycytidine on immune-Associated proteins in exosomes from hepatoma. World J Gastroenterol 2010;16(19):2371-7
    • (2010) World J Gastroenterol , vol.16 , Issue.19 , pp. 2371-2377
    • Xiao, W.H.1    Sanren, G.W.2    Zhu, J.H.3
  • 55
    • 80054689372 scopus 로고    scopus 로고
    • Mage-A1 mage-A3 and ny-eso-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic t lymphocyte-mediated tumor cell killing
    • Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 2011;60(9):1299-307
    • (2011) Cancer Immunol Immunother , vol.60 , Issue.9 , pp. 1299-1307
    • Bao, L.1    Dunham, K.2    Lucas, K.3
  • 56
    • 77952952304 scopus 로고    scopus 로고
    • The dna demethylating agent 5-Aza-2?-deoxycytidine induces expression of ny-eso-1 and other cancer/testis antigens in myeloid leukemia cells
    • Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al. The DNA demethylating agent 5-Aza-2?-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010; 34(7):899-905
    • (2010) Leuk Res , vol.34 , Issue.7 , pp. 899-905
    • Almstedt, M.1    Blagitko-Dorfs, N.2    Duque-Afonso, J.3
  • 57
    • 84859588335 scopus 로고    scopus 로고
    • Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing ny-eso-1 antigen in ovarian cancer and melanoma patients
    • Odunsi K, Matsuzaki J, Karbach J, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012;109(15):5797-802
    • (2012) Proc Natl Acad Sci USA , vol.109 , Issue.15 , pp. 5797-5802
    • Odunsi, K.1    Matsuzaki, J.2    Karbach, J.3
  • 58
    • 84863718471 scopus 로고    scopus 로고
    • Cancer/testis antigens and urological malignancies
    • Kulkarni P, Shiraishi T, Rajagopalan K, et al. Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012;9(7): 386-96
    • (2012) Nat Rev Urol , vol.9 , Issue.7 , pp. 386-396
    • Kulkarni, P.1    Shiraishi, T.2    Rajagopalan, K.3
  • 59
    • 80155131086 scopus 로고    scopus 로고
    • Expression and immunotherapeutic targeting of the ssx family of cancer-Testis antigens in prostate cancer
    • Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-Testis antigens in prostate cancer. Cancer Res 2011;71(21):6785-95
    • (2011) Cancer Res , vol.71 , Issue.21 , pp. 6785-6795
    • Smith, H.A.1    Cronk, R.J.2    Lang, J.M.3    McNeel, D.G.4
  • 60
    • 84904757855 scopus 로고    scopus 로고
    • Decitabine facilitates immune recognition of sarcoma cells by upregulating ct antigens mhc molecules and icam-1
    • Krishnadas DK, Bao L, Bai F, et al. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol 2014;35(6):5753-62
    • (2014) Tumour Biol , vol.35 , Issue.6 , pp. 5753-5762
    • Krishnadas, D.K.1    Bao, L.2    Bai, F.3
  • 61
    • 10844289762 scopus 로고    scopus 로고
    • Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2?-deoxycytidine
    • Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2?-deoxycytidine. Cancer Res 2004;64(24): 9167-71
    • (2004) Cancer Res , vol.64 , Issue.24 , pp. 9167-9171
    • Sigalotti, L.1    Fratta, E.2    Coral, S.3
  • 62
    • 77950813628 scopus 로고    scopus 로고
    • Epigenetically regulated clonal heritability of cta expression profiles in human melanoma
    • Fratta E, Sigalotti L, Colizzi F, et al. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010;223(2): 352-8
    • (2010) J Cell Physiol , vol.223 , Issue.2 , pp. 352-358
    • Fratta, E.1    Sigalotti, L.2    Colizzi, F.3
  • 63
    • 1842372075 scopus 로고    scopus 로고
    • Immunoselection in vivo: Independent loss of mhc class i and melanocyte differentiation antigen expression in metastatic melanoma
    • Jager E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71(2):142-7
    • (1997) Int J Cancer , vol.71 , Issue.2 , pp. 142-147
    • Jager, E.1    Ringhoffer, M.2    Altmannsberger, M.3
  • 64
    • 0033931860 scopus 로고    scopus 로고
    • Monoclonal antibody ma454 reveals a heterogeneous expression pattern of mage-1 antigen in formalin-fixed paraffin embedded lung tumours
    • Jungbluth AA, Stockert E, Chen YT, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000; 83(4):493-7
    • (2000) Br J Cancer , vol.83 , Issue.4 , pp. 493-497
    • Jungbluth, A.A.1    Stockert, E.2    Chen, Y.T.3
  • 65
    • 0035876940 scopus 로고    scopus 로고
    • Immunohistochemical analysis of ny-eso-1 antigen expression in normal and malignant human tissues
    • Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92(6):856-60
    • (2001) Int J Cancer , vol.92 , Issue.6 , pp. 856-860
    • Jungbluth, A.A.1    Chen, Y.T.2    Stockert, E.3
  • 66
    • 17044445366 scopus 로고    scopus 로고
    • Heterogeneous expression of the ssx cancer/testis antigens in human melanoma lesions and cell lines
    • dos Santos NR, Torensma R, de Vries TJ, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 2000; 60(6):1654-62
    • (2000) Cancer Res , vol.60 , Issue.6 , pp. 1654-1662
    • Dos Santos, N.R.1    Torensma, R.2    De Vries, T.J.3
  • 67
    • 0032503029 scopus 로고    scopus 로고
    • Viral strategies of immune evasion
    • Ploegh HL. Viral strategies of immune evasion. Science 1998;280(5361):248-53
    • (1998) Science , vol.280 , Issue.5361 , pp. 248-253
    • Ploegh, H.L.1
  • 68
    • 0031080901 scopus 로고    scopus 로고
    • Implications for immunosurveillance of altered hla class i phenotypes in human tumours
    • Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18(2):89-95
    • (1997) Immunol Today , vol.18 , Issue.2 , pp. 89-95
    • Garrido, F.1    Ruiz-Cabello, F.2    Cabrera, T.3
  • 71
    • 0027485675 scopus 로고
    • Natural history of hla expression during tumour development
    • Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumour development. Immunol Today 1993;14(10):491-9
    • (1993) Immunol Today , vol.14 , Issue.10 , pp. 491-499
    • Garrido, F.1    Cabrera, T.2    Concha, A.3
  • 72
    • 0034006845 scopus 로고    scopus 로고
    • High frequency of altered hla class i phenotypes in laryngeal carcinomas
    • Cabrera T, Salinero J, Fernandez MA, et al. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol 2000;61(5):499-506
    • (2000) Hum Immunol , vol.61 , Issue.5 , pp. 499-506
    • Cabrera, T.1    Salinero, J.2    Fernandez, M.A.3
  • 73
    • 0034794672 scopus 로고    scopus 로고
    • Dna hypermethylation is a mechanism for loss of expression of the hla class i genes in human esophageal squamous cell carcinomas
    • Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001;22(10): 1615-23
    • (2001) Carcinogenesis , vol.22 , Issue.10 , pp. 1615-1623
    • Nie, Y.1    Yang, G.2    Song, Y.3
  • 74
    • 0028954008 scopus 로고
    • Methylation status and transcriptional expression of the mhc class i loci in human trophoblast cells from term placenta
    • Guillaudeux T, Rodriguez AM, Girr M, et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J Immunol 1995;154(7):3283-99
    • (1995) J Immunol , vol.154 , Issue.7 , pp. 3283-3299
    • Guillaudeux, T.1    Rodriguez, A.M.2    Girr, M.3
  • 75
    • 0035886022 scopus 로고    scopus 로고
    • Re-expression of hla class i antigens and restoration of antigen-specific ctl response in melanoma cells following 5-Aza-2?-deoxycytidine treatment
    • Serrano A, Tanzarella S, Lionello I, et al. Re-expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-Aza-2?-deoxycytidine treatment. Int J Cancer 2001; 94(2):243-51
    • (2001) Int J Cancer , vol.94 , Issue.2 , pp. 243-251
    • Serrano, A.1    Tanzarella, S.2    Lionello, I.3
  • 76
    • 59449088943 scopus 로고    scopus 로고
    • Treatment of ovarian cancer cell lines with 5-Aza-2?-deoxycytidine upregulates the expression of cancer-Testis antigens and class i major histocompatibility complex-encoded molecules
    • Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-Aza-2?-deoxycytidine upregulates the expression of cancer-Testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 2009;58(4):589-601
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.4 , pp. 589-601
    • Adair, S.J.1    Hogan, K.T.2
  • 77
    • 34250621776 scopus 로고    scopus 로고
    • Functional up-regulation of human leukocyte antigen class i antigens expression by 5-Aza-2?-deoxycytidine in cutaneous melanoma: Immunotherapeutic implications
    • Fonsatti E, Nicolay HJ, Sigalotti L, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-Aza-2?-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007;13(11):3333-8
    • (2007) Clin Cancer Res , vol.13 , Issue.11 , pp. 3333-3338
    • Fonsatti, E.1    Nicolay, H.J.2    Sigalotti, L.3
  • 78
    • 0032920527 scopus 로고    scopus 로고
    • Prolonged upregulation of the expression of hla class i antigens and costimulatory molecules on melanoma cells treated with 5 -Aza-2?-deoxycytidine (5-Aza-cdr
    • Coral S, Sigalotti L, Gasparollo A, et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5 -Aza-2?-deoxycytidine (5-AZA-CdR). J Immunother 1999;22(1):16-24
    • (1999) J Immunother , vol.22 , Issue.1 , pp. 16-24
    • Coral, S.1    Sigalotti, L.2    Gasparollo, A.3
  • 79
    • 60249095691 scopus 로고    scopus 로고
    • Demethylating agent 5-Aza-2?-deoxycytidine activates hla-g expression in human leukemia cell lines
    • Polakova K, Bandzuchova E, Kuba D, Russ G. Demethylating agent 5-Aza-2?-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res 2009; 33(4):518-24
    • (2009) Leuk Res , vol.33 , Issue.4 , pp. 518-524
    • Polakova, K.1    Bandzuchova, E.2    Kuba, D.3    Russ, G.4
  • 80
    • 44349150012 scopus 로고    scopus 로고
    • Inhibitory b7-family molecules in the tumour microenvironment
    • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467-77
    • (2008) Nat Rev Immunol , vol.8 , Issue.6 , pp. 467-477
    • Zou, W.1    Chen, L.2
  • 81
    • 0034671618 scopus 로고    scopus 로고
    • Activation of mhc class i, ii, and cd40 gene expression by histone deacetylase inhibitors
    • Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000; 165(12):7017-24
    • (2000) J Immunol , vol.165 , Issue.12 , pp. 7017-7024
    • Magner, W.J.1    Kazim, A.L.2    Stewart, C.3
  • 82
    • 77949425245 scopus 로고    scopus 로고
    • Epigenetic silencing of tnfsf7 (cd70) by dna methylation during progression to breast cancer
    • Yu SE, Park SH, Jang YK. Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells 2010;29(2):217-21
    • (2010) Mol Cells , vol.29 , Issue.2 , pp. 217-221
    • Yu, S.E.1    Park, S.H.2    Jang, Y.K.3
  • 83
    • 3142598882 scopus 로고    scopus 로고
    • Induction of t-cell antitumor immunity and protection against tumor growth by secretion of soluble human cd70 molecules
    • Cormary C, Gonzalez R, Faye JC, et al. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther 2004;11(7): 497-507
    • (2004) Cancer Gene Ther , vol.11 , Issue.7 , pp. 497-507
    • Cormary, C.1    Gonzalez, R.2    Faye, J.C.3
  • 84
    • 0037342606 scopus 로고    scopus 로고
    • Involvement of cd70 and cd80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response
    • Douin-Echinard V, Peron JM, Lauwers-Cances V, et al. Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response. Int Immunol 2003;15(3):359-72
    • (2003) Int Immunol , vol.15 , Issue.3 , pp. 359-372
    • Douin-Echinard, V.1    Peron, J.M.2    Lauwers-Cances, V.3
  • 85
    • 0037962005 scopus 로고    scopus 로고
    • Results of decitabine (5-Aza-2?deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
    • Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-Aza-2?deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003;98(3): 522-8
    • (2003) Cancer , vol.98 , Issue.3 , pp. 522-528
    • Kantarjian, H.M.1    O'Brien, S.2    Cortes, J.3
  • 86
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase iii randomized study
    • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106(8):1794-803
    • (2006) Cancer , vol.106 , Issue.8 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 87
    • 0022501789 scopus 로고
    • Phase i and pharmacokinetic study of 5-Aza-2?-deoxycytidine (nsc 127716) in cancer patients
    • van Groeningen CJ, Leyva A, O'Brien AM, et al. Phase I and pharmacokinetic study of 5-Aza-2?-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46(9): 4831-6
    • (1986) Cancer Res , vol.46 , Issue.9 , pp. 4831-4836
    • Van Groeningen, C.J.1    Leyva, A.2    O'Brien, A.M.3
  • 88
    • 0344990164 scopus 로고    scopus 로고
    • Phase i trial of continuous infusion 5-Aza-2?-deoxycytidine
    • Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-Aza-2?-deoxycytidine. Cancer Chemother Pharmacol 2003;51(3):231-9
    • (2003) Cancer Chemother Pharmacol , vol.51 , Issue.3 , pp. 231-239
    • Aparicio, A.1    Eads, C.A.2    Leong, L.A.3
  • 89
    • 0023573963 scopus 로고
    • The eortc early clinical trials cooperative group experience with 5-Aza-2?-deoxycytidine (nsc 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
    • Abele R, Clavel M, Dodion P, et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-Aza-2?-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 1987;23(12):1921-4
    • (1987) Eur J Cancer Clin Oncol , vol.23 , Issue.12 , pp. 1921-1924
    • Abele, R.1    Clavel, M.2    Dodion, P.3
  • 90
    • 0034326784 scopus 로고    scopus 로고
    • Reversal of drug resistance in human tumor xenografts by 2?-deoxy-5-Azacytidine-induced demethylation of the hmlh1 gene promoter
    • Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2?-deoxy-5-Azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60(21):6039-44
    • (2000) Cancer Res , vol.60 , Issue.21 , pp. 6039-6044
    • Plumb, J.A.1    Strathdee, G.2    Sludden, J.3
  • 91
    • 79955848307 scopus 로고    scopus 로고
    • A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma
    • Iwata H, Sato H, Suzuki R, et al. A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol 2011;38(6):1653-61
    • (2011) Int J Oncol , vol.38 , Issue.6 , pp. 1653-1661
    • Iwata, H.1    Sato, H.2    Suzuki, R.3
  • 92
    • 15444378146 scopus 로고    scopus 로고
    • Cancer of the ovary
    • Liu CM. Cancer of the ovary. N Engl J Med 2005;352(12):1268-9
    • (2005) N Engl J Med , vol.352 , Issue.12 , pp. 1268-1269
    • Liu, C.M.1
  • 93
    • 0036794950 scopus 로고    scopus 로고
    • Phase ii trial of cisplatin plus decitabine, a new dna hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix
    • Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002;25(5):496-501
    • (2002) Am J Clin Oncol , vol.25 , Issue.5 , pp. 496-501
    • Pohlmann, P.1    Dileone, L.P.2    Cancella, A.I.3
  • 94
    • 84875597205 scopus 로고    scopus 로고
    • Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase i/ii study and pharmacokinetic analysis
    • Tawbi HA, Beumer JH, Tarhini AA, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol 2013; 24(4):1112-19
    • (2013) Ann Oncol , vol.24 , Issue.4 , pp. 1112-1119
    • Tawbi, H.A.1    Beumer, J.H.2    Tarhini, A.A.3
  • 95
    • 35648948447 scopus 로고    scopus 로고
    • Combining epigenetic and cytotoxic therapy in the treatment of solid tumors
    • Plimack ER, Stewart DJ, Issa JP. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol 2007;25(29):4519-21
    • (2007) J Clin Oncol , vol.25 , Issue.29 , pp. 4519-4521
    • Plimack, E.R.1    Stewart, D.J.2    Issa, J.P.3
  • 96
    • 35848958565 scopus 로고    scopus 로고
    • Radiotherapy in gastric cancer: A systematic review of literature and new perspectives
    • Valentini V, Cellini F. Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Rev Anticancer Ther 2007;7(10):1379-93
    • (2007) Expert Rev Anticancer Ther , vol.7 , Issue.10 , pp. 1379-1393
    • Valentini, V.1    Cellini, F.2
  • 97
    • 34250689152 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells
    • Bar-Sela G, Jacobs KM, Gius D. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells. Cancer J 2007;13(1):65-9
    • (2007) Cancer J , vol.13 , Issue.1 , pp. 65-69
    • Bar-Sela, G.1    Jacobs, K.M.2    Gius, D.3
  • 98
    • 59649094562 scopus 로고    scopus 로고
    • A systematic assessment of radiation dose enhancement by 5-Aza-2?-deoxycytidine and histone deacetylase inhibitors in head-And-neck squamous cell carcinoma
    • De Schutter H, Kimpe M, Isebaert S, Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2?-deoxycytidine and histone deacetylase inhibitors in head-And-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73(3):904-12
    • (2009) Int J Radiat Oncol Biol Phys , vol.73 , Issue.3 , pp. 904-912
    • De Schutter, H.1    Kimpe, M.2    Isebaert, S.3    Nuyts, S.4
  • 99
    • 67649659846 scopus 로고    scopus 로고
    • The combination effect of sodium butyrate and 5-Aza-2?-deoxycytidine on radiosensitivity in rko colorectal cancer and mcf-7 breast cancer cell lines
    • Cho HJ, Kim SY, Kim KH, et al. The combination effect of sodium butyrate and 5-Aza-2?-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol 2009;7:49
    • (2009) World J Surg Oncol , vol.7 , pp. 49
    • Cho, H.J.1    Kim, S.Y.2    Kim, K.H.3
  • 100
    • 84872189951 scopus 로고    scopus 로고
    • 5-Aza-2?-Deoxycytidine enhances the radiosensitivity of breast cancer cells
    • Wang L, Zhang Y, Li R, et al. 5-Aza-2?-Deoxycytidine enhances the radiosensitivity of breast cancer cells. Cancer Biother Radiopharm 2013;28(1):34-44
    • (2013) Cancer Biother Radiopharm , vol.28 , Issue.1 , pp. 34-44
    • Wang, L.1    Zhang, Y.2    Li, R.3
  • 101
    • 58149313656 scopus 로고    scopus 로고
    • Dna methyltransferase inhibitor 5-Aza-cdr enhances the radiosensitivity of gastric cancer cells
    • Qiu H, Yashiro M, Shinto O, et al. DNA methyltransferase inhibitor 5-Aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci 2009;100(1):181-8
    • (2009) Cancer Sci , vol.100 , Issue.1 , pp. 181-188
    • Qiu, H.1    Yashiro, M.2    Shinto, O.3
  • 102
    • 84898893534 scopus 로고    scopus 로고
    • Epigenetic drugs as immunomodulators for combination therapies in solid tumors
    • Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 2014;142(3):339-50
    • (2014) Pharmacol Ther , vol.142 , Issue.3 , pp. 339-350
    • Sigalotti, L.1    Fratta, E.2    Coral, S.3    Maio, M.4
  • 103
    • 84906690218 scopus 로고    scopus 로고
    • Hypomethylating agent 5-Aza-2?-deoxycytidine (dac) ameliorates multiple sclerosis in mouse models
    • Mangano K, Fagone P, Bendtzen K, et al. Hypomethylating agent 5-Aza-2?-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. J Cell Physiol 2014;229(12):1918-25
    • (2014) J Cell Physiol , vol.229 , Issue.12 , pp. 1918-1925
    • Mangano, K.1    Fagone, P.2    Bendtzen, K.3
  • 104
    • 84897082935 scopus 로고    scopus 로고
    • Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice
    • Guo H, Wang W, Zhao N, et al. Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Transpl Immunol 2013;29(1-4):99-104
    • (2013) Transpl Immunol , vol.29 , Issue.1-4 , pp. 99-104
    • Guo, H.1    Wang, W.2    Zhao, N.3
  • 105
    • 59849085588 scopus 로고    scopus 로고
    • Epigenetic regulation of foxp3 expression in regulatory t cells by dna methylation
    • Lal G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009;182(1):259-73
    • (2009) J Immunol , vol.182 , Issue.1 , pp. 259-273
    • Lal, G.1    Zhang, N.2    Van Der Touw, W.3
  • 107
    • 0035134688 scopus 로고    scopus 로고
    • Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
    • Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6(1):34-55
    • (2001) Oncologist , vol.6 , Issue.1 , pp. 34-55
    • Jonasch, E.1    Haluska, F.G.2
  • 108
    • 84939875915 scopus 로고    scopus 로고
    • A phase i study of decitabine with pegylated interferon alpha-2b in advanced melanoma: Impact on dna methylation and lymphocyte populations
    • Plimack ER, Desai JR, Issa JP, et al. A phase I study of decitabine with pegylated interferon alpha-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs 2014;32(5):969-75
    • (2014) Invest New Drugs , vol.32 , Issue.5 , pp. 969-975
    • Plimack, E.R.1    Desai, J.R.2    Issa, J.P.3
  • 109
    • 33748046812 scopus 로고    scopus 로고
    • Phase i trial of sequential low-dose 5-Aza-2?-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma
    • Gollob JA, Sciambi CJ, Peterson BL, et al. Phase I trial of sequential low-dose 5-Aza-2?-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006;12(15):4619-27
    • (2006) Clin Cancer Res , vol.12 , Issue.15 , pp. 4619-4627
    • Gollob, J.A.1    Sciambi, C.J.2    Peterson, B.L.3
  • 110
    • 0034046182 scopus 로고    scopus 로고
    • Dna vaccines: Immunology, application, and optimization
    • Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-74
    • (2000) Annu Rev Immunol , vol.18 , pp. 927-974
    • Gurunathan, S.1    Klinman, D.M.2    Seder, R.A.3
  • 111
    • 67649506210 scopus 로고    scopus 로고
    • Treatment with demethylating agent, 5-Aza-2?-deoxycytidine enhances therapeutic hpv dna vaccine potency
    • Lu D, Hoory T, Monie A, et al. Treatment with demethylating agent, 5-Aza-2?-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009; 27(32):4363-9
    • (2009) Vaccine , vol.27 , Issue.32 , pp. 4363-4369
    • Lu, D.1    Hoory, T.2    Monie, A.3
  • 112
    • 84872863162 scopus 로고    scopus 로고
    • Complete remission following decitabine/.dendritic cell vaccine for relapsed neuroblastoma
    • Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/.dendritic cell vaccine for relapsed neuroblastoma. Pediatrics 2013;131(1): e336-41
    • (2013) Pediatrics , vol.131 , Issue.1 , pp. e336-e341
    • Krishnadas, D.K.1    Shapiro, T.2    Lucas, K.3
  • 113
    • 0027423120 scopus 로고
    • Uncoordinate induction and differential regulation of hla class-i and class-ii expression by gamma-interferon in differentiating human neuroblastoma cells
    • Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 1993; 55(5):817-23
    • (1993) Int J Cancer , vol.55 , Issue.5 , pp. 817-823
    • Ponzoni, M.1    Guarnaccia, F.2    Corrias, M.V.3    Cornaglia-Ferraris, P.4
  • 114
    • 33645697721 scopus 로고    scopus 로고
    • A phase i trial of vaccination of ca9-derived peptides for hla-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma
    • Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12(6):1768-75
    • (2006) Clin Cancer Res , vol.12 , Issue.6 , pp. 1768-1775
    • Uemura, H.1    Fujimoto, K.2    Tanaka, M.3
  • 116
    • 84923360131 scopus 로고    scopus 로고
    • 2B: A Phase I Study With Molecular Correlates Available from NCT00886457
    • 5-Aza-2-deoxycytidine With Pegylated Interferon-Alfa 2B: A Phase I Study With Molecular Correlates. Available from: https://clinicaltrials.gov/ct2/show/.NCT00886457
    • 5-Aza-2-deoxycytidine with Pegylated Interferon-Alfa
  • 117
    • 84887492896 scopus 로고    scopus 로고
    • What lies within: Novel strategies in immunotherapy for non-small cell lung cancer
    • Forde PM, Reiss KA, Zeidan AM, Brahmer JR. What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013;18(11): 1203-13
    • (2013) Oncologist , vol.18 , Issue.11 , pp. 1203-1213
    • Forde, P.M.1    Reiss, K.A.2    Zeidan, A.M.3    Brahmer, J.R.4
  • 118
    • 84890130945 scopus 로고    scopus 로고
    • Alterations of immune response of non-small cell lung cancer with azacytidine
    • Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 2013;4(11): 2067-79
    • (2013) Oncotarget , vol.4 , Issue.11 , pp. 2067-2079
    • Wrangle, J.1    Wang, W.2    Koch, A.3
  • 119
    • 84905994658 scopus 로고    scopus 로고
    • Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
    • Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 2014;111(32):11774-9
    • (2014) Proc Natl Acad Sci USA , vol.111 , Issue.32 , pp. 11774-11779
    • Kim, K.1    Skora, A.D.2    Li, Z.3
  • 120
    • 33847065486 scopus 로고    scopus 로고
    • The epigenomics of cancer
    • Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128(4):683-92
    • (2007) Cell , vol.128 , Issue.4 , pp. 683-692
    • Jones, P.A.1    Baylin, S.B.2
  • 121
    • 0037224722 scopus 로고    scopus 로고
    • Dnmt1 is required to maintain cpg methylation and aberrant gene silencing in human cancer cells
    • Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33(1): 61-5
    • (2003) Nat Genet , vol.33 , Issue.1 , pp. 61-65
    • Robert, M.F.1    Morin, S.2    Beaulieu, N.3
  • 122
    • 0037154963 scopus 로고    scopus 로고
    • Cooperation between complexes that regulate chromatin structure and transcription
    • Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108(4):475-87
    • (2002) Cell , vol.108 , Issue.4 , pp. 475-487
    • Narlikar, G.J.1    Fan, H.Y.2    Kingston, R.E.3
  • 124
    • 0032948005 scopus 로고    scopus 로고
    • Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
    • Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21(1):103-7
    • (1999) Nat Genet , vol.21 , Issue.1 , pp. 103-107
    • Cameron, E.E.1    Bachman, K.E.2    Myohanen, S.3
  • 125
    • 77955501765 scopus 로고    scopus 로고
    • Combinations of dna methyltransferase and histone deacetylase inhibitors induce dna damage in small cell lung cancer cells: Correlation of resistance with ifn-stimulated gene expression
    • Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 2010;9(8): 2309-21
    • (2010) Mol Cancer Ther , vol.9 , Issue.8 , pp. 2309-2321
    • Luszczek, W.1    Cheriyath, V.2    Mekhail, T.M.3    Borden, E.C.4
  • 126
    • 59349096447 scopus 로고    scopus 로고
    • Synergistic induction of ny-eso-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-Aza-2?-deoxycytidine in glioma cells
    • Oi S, Natsume A, Ito M, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-Aza-2?-deoxycytidine in glioma cells. J Neurooncol 2009;92(1): 15-22
    • (2009) J Neurooncol , vol.92 , Issue.1 , pp. 15-22
    • Oi, S.1    Natsume, A.2    Ito, M.3
  • 127
    • 84860327244 scopus 로고    scopus 로고
    • Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo
    • Yang D, Torres CM, Bardhan K, et al. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 2012; 188(9):4441-9
    • (2012) J Immunol , vol.188 , Issue.9 , pp. 4441-4449
    • Yang, D.1    Torres, C.M.2    Bardhan, K.3
  • 129
    • 40849139208 scopus 로고    scopus 로고
    • Epigenetics in cancer
    • Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
    • (2008) N Engl J Med , vol.358 , Issue.11 , pp. 1148-1159
    • Esteller, M.1
  • 130
    • 20344405446 scopus 로고    scopus 로고
    • Dna methylation disturbances as novel therapeutic target in lung cancer: Preclinical and clinical results
    • Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 2005;55(1):1-11
    • (2005) Crit Rev Oncol Hematol , vol.55 , Issue.1 , pp. 1-11
    • Digel, W.1    Lubbert, M.2
  • 131
    • 34548223215 scopus 로고    scopus 로고
    • Challenges and prospects of immunotherapy as cancer treatment
    • Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 2007;1776(1):108-23
    • (2007) Biochim Biophys Acta , vol.1776 , Issue.1 , pp. 108-123
    • Rescigno, M.1    Avogadri, F.2    Curigliano, G.3
  • 132
    • 0742269866 scopus 로고    scopus 로고
    • Decitabine
    • Issa JP. Decitabine. Curr Opin Oncol 2003; 15(6):446-51
    • (2003) Curr Opin Oncol , vol.15 , Issue.6 , pp. 446-451
    • Issa, J.P.1
  • 133
    • 84856377986 scopus 로고    scopus 로고
    • Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
    • Alcazar O, Achberger S, Aldrich W, et al. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer 2012;131(1):18-29
    • (2012) Int J Cancer , vol.131 , Issue.1 , pp. 18-29
    • Alcazar, O.1    Achberger, S.2    Aldrich, W.3
  • 134
    • 84866565997 scopus 로고    scopus 로고
    • Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
    • Triozzi PL, Aldrich W, Achberger S, et al. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother 2012;61(9):1441-50
    • (2012) Cancer Immunol Immunother , vol.61 , Issue.9 , pp. 1441-1450
    • Triozzi, P.L.1    Aldrich, W.2    Achberger, S.3
  • 135
    • 33750120013 scopus 로고    scopus 로고
    • Promoter hypomethylation and reactivation of mage-A1 and mage-A3 genes in colorectal cancer cell lines and cancer tissues
    • Kim KH, Choi JS, Kim IJ, et al. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J Gastroenterol 2006;12(35): 5651-7
    • (2006) World J Gastroenterol , vol.12 , Issue.35 , pp. 5651-5657
    • Kim, K.H.1    Choi, J.S.2    Kim, I.J.3
  • 136
    • 9444249349 scopus 로고    scopus 로고
    • Expression of mage genes in human colorectal carcinoma
    • Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996; 224(2):183-8
    • (1996) Ann Surg , vol.224 , Issue.2 , pp. 183-188
    • Mori, M.1    Inoue, H.2    Mimori, K.3
  • 137
    • 50349087907 scopus 로고    scopus 로고
    • Intertumor and intratumor ny-eso-1 expression heterogeneity is associated with promoter-specific and global dna methylation status in ovarian cancer
    • Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, et al. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008;14(11):3283-90
    • (2008) Clin Cancer Res , vol.14 , Issue.11 , pp. 3283-3290
    • Woloszynska-Read, A.1    Mhawech-Fauceglia, P.2    Yu, J.3
  • 138
    • 84864982035 scopus 로고    scopus 로고
    • A novel cancer/testis antigen kp-ova-52 identified by serex in human ovarian cancer is regulated by dna methylation
    • Kim KM, Song MH, Kim MJ, et al. A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation. Int J Oncol 2012;41(3): 1139-47
    • (2012) Int J Oncol , vol.41 , Issue.3 , pp. 1139-1147
    • Kim, K.M.1    Song, M.H.2    Kim, M.J.3
  • 139
    • 84880973690 scopus 로고    scopus 로고
    • Dna methylation and nucleosome occupancy regulate the cancer germline antigen gene magea11
    • James SR, Cedeno CD, Sharma A, et al. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 2013; 8(8):849-63
    • (2013) Epigenetics , vol.8 , Issue.8 , pp. 849-863
    • James, S.R.1    Cedeno, C.D.2    Sharma, A.3
  • 140
    • 38149047500 scopus 로고    scopus 로고
    • Dna methylation-dependent regulation of boris/ctcfl expression in ovarian cancer
    • Woloszynska-Read A, James SR, Link PA, et al. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007;7:21
    • (2007) Cancer Immun , vol.7 , pp. 21
    • Woloszynska-Read, A.1    James, S.R.2    Link, P.A.3
  • 141
    • 42549133624 scopus 로고    scopus 로고
    • The dna demethylating agent 5-Aza-2?-deoxycytidine activates ny-eso-1 antigenicity in orthotopic human glioma
    • Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-Aza-2?-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008;122(11):2542-53
    • (2008) Int J Cancer , vol.122 , Issue.11 , pp. 2542-2553
    • Natsume, A.1    Wakabayashi, T.2    Tsujimura, K.3
  • 142
    • 3142710121 scopus 로고    scopus 로고
    • Her-2, gp100, and mage-1 are expressed in human glioblastoma and recognized by cytotoxic t cells
    • Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004;64(14): 4980-6
    • (2004) Cancer Res , vol.64 , Issue.14 , pp. 4980-4986
    • Liu, G.1    Ying, H.2    Zeng, G.3
  • 143
    • 13444310785 scopus 로고    scopus 로고
    • The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma
    • Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004;4:7
    • (2004) Cancer Immun , vol.4 , pp. 7
    • Ayyoub, M.1    Taub, R.N.2    Keohan, M.L.3
  • 144
    • 84887959659 scopus 로고    scopus 로고
    • Potential role of 5-Aza-2?-deoxycytidine induced mage-A4 expression in immunotherapy for anaplastic thyroid cancer
    • Gunda V, Cogdill AP, Bernasconi MJ, et al. Potential role of 5-Aza-2?-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery 2013;154(6):1456-62
    • (2013) Surgery , vol.154 , Issue.6 , pp. 1456-1462
    • Gunda, V.1    Cogdill, A.P.2    Bernasconi, M.J.3
  • 145
    • 80054678677 scopus 로고    scopus 로고
    • Increased prame antigen-specific killing of malignant cell lines by low avidity ctl clones following treatment with 5-Aza-2?-deoxycytidine
    • Yan M, Himoudi N, Basu BP, et al. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2?-Deoxycytidine. Cancer Immunol Immunother 2011;60(9):1243-55
    • (2011) Cancer Immunol Immunother , vol.60 , Issue.9 , pp. 1243-1255
    • Yan, M.1    Himoudi, N.2    Basu, B.P.3
  • 146
    • 0030966606 scopus 로고    scopus 로고
    • Expression of mage and bage genes in japanese breast cancers
    • Fujie T, Mori M, Ueo H, et al. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann Oncol 1997;8(4):369-72
    • (1997) Ann Oncol , vol.8 , Issue.4 , pp. 369-372
    • Fujie, T.1    Mori, M.2    Ueo, H.3
  • 147
    • 0035132573 scopus 로고    scopus 로고
    • Induction of mage-3 expression in lung and esophageal cancer cells
    • Weiser TS, Ohnmacht GA, Guo ZS, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 2001;71(1):295-301
    • (2001) Ann Thorac Surg , vol.71 , Issue.1 , pp. 295-301
    • Weiser, T.S.1    Ohnmacht, G.A.2    Guo, Z.S.3
  • 148
    • 84863287359 scopus 로고    scopus 로고
    • Nyeso-1/lage-1s and prame are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
    • Pollack SM, Li Y, Blaisdell MJ, et al. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 2012;7(2): e32165
    • (2012) PLoS One , vol.7 , Issue.2 , pp. e32165
    • Pollack, S.M.1    Li, Y.2    Blaisdell, M.J.3
  • 149
    • 70349242372 scopus 로고    scopus 로고
    • Quantitative expression and immunogenicity of mage-3 and -6 in upper aerodigestive tract cancer
    • Filho PA, Lopez-Albaitero A, Xi L, et al. Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer 2009;125(8): 1912-20
    • (2009) Int J Cancer , vol.125 , Issue.8 , pp. 1912-1920
    • Filho, P.A.1    Lopez-Albaitero, A.2    Xi, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.